



NeuroVista Raises \$16.5 Million in Equity Financing

Seattle, WA—August 18, 2010—NeuroVista Corporation, a developer of innovative medical technologies for the management and treatment of epilepsy, today announced it has closed an equity financing round with total proceeds of \$16.5 million. The financing was led by GBS Venture Partners, joined by existing investors Advanced Technology Ventures, Delphi Ventures and Foundation Medical Partners. The financing will support the ongoing clinical trials of the NeuroVista[®] Seizure Advisory System[™] and continued technology development.

“We are very pleased to have GBS join our investor syndicate and we welcome Dr. Steve Gourlay from GBS to our Board of Directors,” said John F. Harris, President and Chief Executive Officer of NeuroVista. “Steve’s extensive experience in industry and academic clinical research will be of tremendous value to us as we move forward with our clinical trials.”

“The NeuroVista Seizure Advisory System is a groundbreaking new platform for empowering people with epilepsy,” said Dr. Gourlay. “We believe that NeuroVista technology will revolutionize the management and treatment of epilepsy by resolving the uncertainty of when seizures are going to strike, improving patients’ quality of life, and enabling new models for the use of drug therapy.”

About GBS Venture Partners

GBS Venture Partners is a leading life science venture capital firm. Founded in 1996, GBS invests in young businesses developing and commercializing products which, when combined with the right management and finance, will make a significant difference to patients' lives and deliver financial returns for its investors. Particular areas of interest and expertise include medical devices and human therapeutics. For more information, visit www.gbsventures.com.au/.

About NeuroVista

NeuroVista is a clinical stage medical device company pioneering new technologies that will revolutionize the management and treatment of epilepsy. Epilepsy is a neurological condition affecting approximately 1% of the U.S. population—more than Parkinson’s disease, multiple sclerosis, and Lou Gehrig’s disease combined. NeuroVista is a privately held company based in Seattle. For more information, visit www.neurovista.com.